Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000585919 | SCV000696994 | uncertain significance | not specified | 2022-04-12 | criteria provided, single submitter | clinical testing | Variant summary: CFTR c.3854C>T (p.Ala1285Val) results in a non-conservative amino acid change located in the AAA+ ATPase domain (IPR003593) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00066 in 250862 control chromosomes (gnomAD), predominantly at a frequency of 0.0053 within the South Asian subpopulation in the gnomAD database, including 1 homozygote. This frequency is somewhat lower than the maximum expected for a pathogenic variant in CFTR causing Congenital Bilateral Absence of the Vas Deferens (CBAVD) (0.013), allowing no conclusion about variant significance. c.3854C>T has been reported in the literature in at least two Asian Indian individuals affected with CBAVD, however no second (likely) pathogenic variant was specified in these cases (Sachdeva 2011, Gaikwad_2020). The variant was also found during carrier screening in homozygosity in an Asian Indian (Schwartz_2009) and an Australian individual (Archibald_2017), but no phenotype information was provided. These reports do not provide unequivocal conclusions about association of the variant with CBAVD. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five other ClinVar submitters have assessed the variant since 2014: three classified the variant as of uncertain significance, one as likely benign, and one as benign. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Mayo Clinic Laboratories, |
RCV001507714 | SCV001713438 | uncertain significance | not provided | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000577447 | SCV001721256 | benign | Cystic fibrosis | 2024-12-24 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV001507714 | SCV002046548 | uncertain significance | not provided | 2022-12-29 | criteria provided, single submitter | clinical testing | The frequency of this variant in the general population, 0.0053 (162/30594 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals with congenital bilateral absence of the vas deferens (CBAVD) (PMID: 21254931 (2011), 34145097 (2020)) and in an individual with pancreatitis (PMID: 33097431 (2020)). The variant has also been reported in carrier screenings (PMID: 19324992 (2009), 29261177 (2018), 30146269 (2019), 32784480 (2020), 32906206 (2020), 33138774 (2020)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. |
Johns Hopkins Genomics, |
RCV000577447 | SCV002051796 | likely benign | Cystic fibrosis | 2021-09-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000577447 | SCV002622766 | likely benign | Cystic fibrosis | 2023-04-11 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Revvity Omics, |
RCV001507714 | SCV003831650 | uncertain significance | not provided | 2023-04-06 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV003448254 | SCV004176470 | uncertain significance | Hereditary pancreatitis | 2023-03-01 | criteria provided, single submitter | clinical testing | The missense c.3854C>T (p.Ala1285Val) variant in CFTR gene has been reported previously in heterozygous state in individual(s) affected with SPINK1-associated Chronic Pancreatitis (Jones et al., 2020). This variant is reported with the allele frequency of 0.06% in the gnomAD Exomes. This variant has been reported to the ClinVar database with varying interpretation: Benign / Likely Benign / Uncertain Significance (multiple submitters). The amino acid Ala at position 1285 is changed to a Val changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Ala1285Val in CFTR is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The variant is predicted as damaging by SIFT. SPINK1 carriers with co-occurring mutations in CFTR exhibited prominent fibrosis of the pancreas and only focal intralobular and/or extralobular lipomatous infiltration into the pancreatic parenchyma. For these reasons, this variant has been classified as Uncertain Significance. |
Gene |
RCV001507714 | SCV005376787 | uncertain significance | not provided | 2024-04-18 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Observed in the heterozygous state in an individual with chronic pancreatitis in published literature (PMID: 33097431); This variant is associated with the following publications: (PMID: 19324992, 30146269, 32906206, 32784480, 33138774, 29261177, 34145097, 33097431, 21254931) |
Clin |
RCV000577447 | SCV000679387 | not provided | Cystic fibrosis | no assertion provided | literature only | ||
Natera, |
RCV000577447 | SCV001460116 | uncertain significance | Cystic fibrosis | 2017-05-09 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004537230 | SCV004720028 | likely benign | CFTR-related disorder | 2022-02-09 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |